NASDAQ:INSY - Insys Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $7.66 +0.05 (+0.66 %) (As of 07/16/2018 06:00 AM ET)Previous Close$7.66Today's Range$7.56 - $7.8052-Week Range$4.10 - $14.00Volume242,805 shsAverage Volume716,951 shsMarket Capitalization$565.38 millionP/E Ratio-15.63Dividend YieldN/ABeta1.21 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. Receive INSY News and Ratings via Email Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:INSY CUSIPN/A Webwww.insysrx.com Phone480-500-3127 Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.76 Price-To-Earnings Trailing P/E Ratio-15.63 Forward P/E Ratio-8.42 P/E GrowthN/A Sales & Book Value Annual Sales$140.69 million Price / Sales4.02 Cash FlowN/A Price / CashN/A Book Value$0.86 per share Price / Book8.91 Profitability EPS (Most Recent Fiscal Year)($0.49) Net Income$-228,010,000.00 Net Margins-188.01% Return on Equity-43.27% Return on Assets-17.51% Miscellaneous Employees343 Outstanding Shares73,810,000Market Cap$565.38 Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions What is Insys Therapeutics' stock symbol? Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY." When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work? Insys Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split. How were Insys Therapeutics' earnings last quarter? Insys Therapeutics Inc (NASDAQ:INSY) issued its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The specialty pharmaceutical company had revenue of $23.90 million for the quarter, compared to analyst estimates of $25.82 million. Insys Therapeutics had a negative net margin of 188.01% and a negative return on equity of 43.27%. The firm's quarterly revenue was down 33.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.09) earnings per share. View Insys Therapeutics' Earnings History. When is Insys Therapeutics' next earnings date? Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Insys Therapeutics. What price target have analysts set for INSY? 5 Wall Street analysts have issued 12 month price targets for Insys Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Insys Therapeutics' stock price to reach $9.6667 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price. View Analyst Ratings for Insys Therapeutics. What is the consensus analysts' recommendation for Insys Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insys Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Insys Therapeutics' key competitors? Some companies that are related to Insys Therapeutics include Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC), Insmed (INSM), Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT) and AnaptysBio (ANAB). Who are Insys Therapeutics' key executives? Insys Therapeutics' management team includes the folowing people: Mr. Steven J. Meyer, Exec. Chairman (Age 61)Mr. Saeed Motahari, CEO, Pres & Director (Age 52)Mr. Andrew G. Long, Chief Financial OfficerMr. Franc Del Fosse, Gen. Counsel & Corp. Sec. (Age 46)Mr. B. Sanga Emmanuel, VP & Chief Compliance Officer Has Insys Therapeutics been receiving favorable news coverage? Media headlines about INSY stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.10 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 46.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. How do I buy shares of Insys Therapeutics? Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Insys Therapeutics' stock price today? One share of INSY stock can currently be purchased for approximately $7.66. How big of a company is Insys Therapeutics? Insys Therapeutics has a market capitalization of $565.38 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe. How can I contact Insys Therapeutics? Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected] MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 333 (Vote Outperform)Underperform Votes: 254 (Vote Underperform)Total Votes: 587MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?